Haleon (NYSE: HLN) discloses 8.9B voting shares as of Dec 31, 2025

Rhea-AI Filing Summary

Haleon plc reported its share count and voting rights as of 31 December 2025. The company had a total of 8,952,353,648 ordinary shares of £0.01 each in issue, of which 45,745,646 were held as treasury shares without voting rights.

After excluding treasury shares, the number of ordinary shares with voting rights was 8,906,608,002. Shareholders and others with disclosure obligations are asked to use this figure as the denominator when calculating whether they need to notify their interest in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 01/02/2026 - 07:59 AM Learn about SEC filing dates

FAQ

How many Haleon (HLN) shares were in issue as of 31 December 2025?

As of 31 December 2025, Haleon plc had 8,952,353,648 ordinary shares of £0.01 each in issue.

How many Haleon (HLN) shares carried voting rights at year-end 2025?

After excluding treasury shares, Haleon reported 8,906,608,002 ordinary shares with voting rights as of 31 December 2025.

How many Haleon (HLN) shares were held in treasury?

Haleon held 45,745,646 ordinary shares as treasury shares, which do not carry voting rights.

Why is the Haleon (HLN) voting share count important for investors?

The figure of 8,906,608,002 voting shares is the denominator shareholders must use to determine whether they need to notify their interest, or changes in their interest, under the FCA's Disclosure Guidance and Transparency Rules.

Who signed the Haleon (HLN) total voting rights and capital update?

The update was signed by Amanda Mellor, who is the Company Secretary of Haleon plc.

What type of company is Haleon (HLN)?

Haleon (LSE/NYSE: HLN) is described as a global leader in consumer health with brands across Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health and Other.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2026

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	02 January 2026 - "Total Voting Rights and Capital"

99.1

Haleon plc: Total Voting Rights and Capital

02 January 2026: As at 31 December 2025 the total number of shares issued by Haleon plc ("Haleon" or the "Company") is 8,952,353,648 ordinary shares of £0.01 each, of which 45,745,646 are held as treasury shares.

Therefore, the number of ordinary shares with voting rights is 8,906,608,002 and this figure should be used by shareholders (and others with notification obligations) as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Notifiable interests in Haleon may be sent to: company.secretary@haleon.com

Amanda Mellor

Company Secretary

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: January 02, 2026	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary